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Background: Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and
neck (HNSCC) following progression after first-line platinum-based therapy, particularly in Asian countries.
Patients and methods: In this randomised, open-label, phase III trial, we enrolled Asian patients aged 18 years, with
histologically or cytologically confirmed recurrent/metastatic HNSCC following first-line platinum-based therapy who were not
amenable for salvage surgery or radiotherapy, and had an Eastern Cooperative Oncology Group (ECOG) performance status of
0/1. Patients were randomised (2 : 1) to receive oral afatinib (40mg/day) or intravenous methotrexate (40mg/m2/week),
stratified by ECOG performance status and prior EGFR-targeted antibody therapy. The primary end point was progression-free
survival (PFS) assessed by an independent central review committee blinded to treatment allocation.
Results: A total of 340 patients were randomised (228 afatinib; 112 methotrexate). After a median follow-up of 6.4months,
afatinib significantly decreased the risk of progression/death by 37% versus methotrexate (hazard ratio 0.63; 95% confidence
interval 0.48–0.82; P¼ 0.0005; median 2.9 versus 2.6months; landmark analysis at 12 and 24weeks, 58% versus 41%, 21% versus
9%). Improved PFS was complemented by quality of life benefits. Objective response rate was 28% with afatinib and 13% with
methotrexate. There was no significant difference in overall survival. The most common grade3 drug-related adverse events
were rash/acne (4% with afatinib versus 0% with methotrexate), diarrhoea (4% versus 0%), fatigue (1% versus 5%), anaemia
(<1% versus 5%) and leukopenia (0% versus 5%).
VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusions: Consistent with the phase III LUX-Head & Neck 1 trial, afatinib significantly improved PFS versus methotrexate,
with a manageable safety profile. These results demonstrate the efficacy and feasibility of afatinib as a second-line treatment
option for certain patients with recurrent or metastatic HNSCC.
Clinical trial registration: ClinicalTrials.gov identifier: NCT01856478.
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Introduction
Currently, the most common first-line treatment option for re-
current/metastatic head and neck squamous cell carcinoma
(HNSCC) is platinum-based chemotherapy, which, in some
regions including the United States and European Union, can be
combined with the epidermal growth factor receptor (EGFR)-
targeted monoclonal antibody cetuximab. However, 50% of
patients relapse after first-line therapy and prognosis for these
patients is particularly poor [1]. Second-line treatment options
are limited but commonly include methotrexate, taxanes, and re-
challenge with platinum-based chemotherapy. Cetuximab
monotherapy and, more recently, the immunotherapy agents
nivolumab and pembrolizumab are approved in some countries
[2], but response rates to these agents as second-line treatment
remain low [35] and many patients, particularly those in Asian
countries, cannot access such treatments. Furthermore, recent
data indicate that immunotherapy agents are likely to be increas-
ingly used in the first-line rather than second-line setting [2].
Consequently, alternative second-line treatment options are
needed.
The feasibility of targeting the EGFR in HNSCC was first dem-
onstrated with cetuximab [1], and encouraging results have been
observed with the oral irreversible ErbB family blocker, afatinib,
in a second-line setting. In a phase II study, afatinib demon-
strated comparable efficacy to cetuximab as subsequent therapy
in patients with recurrent/metastatic HNSCC [3]. In the global,
phase III LUX-Head & Neck 1 study, second-line afatinib signifi-
cantly prolonged progression-free survival (PFS) versus metho-
trexate in patients with recurrent/metastatic HNSCC progressing
on or after platinum-based chemotherapy [hazard ratio (HR)
0.80; 95% confidence interval (CI) 0.65–0.98; P¼ 0.030] [6].
Notable benefit with afatinib versus methotrexate was seen in
patients who had not received a prior EGFR-targeted antibody
and in those with p16-negative disease.
More than 55% of global HNSCC cases are reported in Asia
[7]. Most cases of HNSCC in Asian patients are p16-negative dis-
ease, with previous studies reporting that only 21%–25% of cases
are human papilloma virus (HPV)-positive [8, 9]. In contrast,
rates of 50%–70% are reported in the United States and Europe
[10]. Combined with the limited availability of cetuximab and
immunotherapy agents, this provides a rationale for the use of
afatinib in Asian patients. Here, we compared second-line afati-
nib and methotrexate in Asian patients with recurrent/metastatic
HNSCC.
Methods
LUX-Head & Neck 3 was a randomised, open-label, phase III study done
at 53 centres in eight countries (China, India, Korea, Thailand, Egypt,
Taiwan, Hong Kong, and the Philippines). Eligible patients were aged
18 years with histologically/cytologically confirmed recurrent/meta-
static squamous cell carcinoma of the oral cavity, oropharynx, hypophar-
ynx, or larynx, unamenable for salvage surgery or radiotherapy. All
patients had an Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0/1, adequate organ function, and had documented pro-
gressive disease after platinum-based chemotherapy based on
investigator’s assessment. Previous treatment with EGFR-targeted anti-
body therapy (but not EGFR-targeted tyrosine kinase inhibitors) was
allowed. The study was conducted in accordance with the principles of
the Declaration of Helsinki and Good Clinical Practice guidelines as
defined by the International Conference on Harmonization. All patients
provided written informed consent.
Patients were randomised (2 : 1) to receive oral afatinib (40 mg once
daily) or methotrexate (40 mg/m2/week; intravenous bolus injection),
stratified by ECOG performance score (0 versus 1) and prior use of
EGFR-targeted antibody therapy in the recurrent/metastatic setting (yes
versus no) at baseline. Treatment continued until disease progression
confirmed by imaging, adverse events (AEs) requiring treatment discon-
tinuation, or other reasons necessitating withdrawal.
The primary end point was PFS, assessed by independent central re-
view blinded to treatment allocation (supplementary material, available
at Annals of Oncology online). Secondary end points included overall sur-
vival (OS), objective response rate [ORR, Response Evaluation Criteria
in Solid Tumours (RECIST) version 1.1], health-related quality of life
(HRQoL) and safety.
The study was designed to demonstrate a PFS benefit of afatinib over
methotrexate. A total of 274 progression/death events were needed to
achieve 80% power with a one-sided type-I error a¼ 0.025, assuming a
median PFS of 3.0 months with afatinib and 2.1 months with
methotrexate [3, 11]. The study was not powered to detect statistically
significant differences in OS. Further details on the methods are provided
in the supplementary material, available at Annals of Oncology online.
The study is registered at ClinicalTrials.gov, NCT01856478.
Results
Between 11 June 2013 and 10 February 2018, 340 patients were
enrolled and randomly assigned to receive afatinib (228 patients)
or methotrexate (112 patients; supplementary Figure S1, avail-
able at Annals of Oncology online). All randomised patients (in-
tent-to-treat population) were included in the efficacy analyses;
332 were included in the safety population. Patient baseline
demographics and disease characteristics were well balanced be-
tween the two treatment arms (Table 1).
At data cut-off (19 September 2018, after a median follow-up
of 6.4 months), two patients in the afatinib group remained on
treatment; all other patients had permanently discontinued treat-
ment, mostly because of disease progression. Ninety-five percent
of patients in the afatinib group and 76% of patients in the
methotrexate group had received at least 80% of the assigned
drug.
At data cut-off, PFS by independent review was significantly
improved with afatinib versus methotrexate (HR 0.63; 95% CI
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0.48–0.82; P¼ 0.0005; median 2.9 versus 2.6 months, respective-
ly; Figure 1A). PFS rates were 58% versus 41% at 12 weeks, and
21% versus 9% at 24 weeks. Results were consistent when assessed
by investigator review (supplementary Figure S2, available at
Annals of Oncology online), and across most major prespecified
subgroups (Figure 1B). There was no significant difference in OS
between the groups (HR 0.88; 95% CI 0.68–1.13; P¼ 0.32; sup-
plementary Figure S3, available at Annals of Oncology online).
The ORR was 28% with afatinib and 13% with methotrexate
[odds ratio (OR) 2.76; 95% CI 1.47–5.18; P¼ 0.0016; Figure 2A].
Results were consistent across prespecified patient subgroups
(Figure 2B). A 50% decrease in tumour size was observed in
17% and 8% of patients, respectively (Figure 2C). Median dur-
ation of response was 2.8 and 4.0 months with afatinib and
methotrexate; 22% and 7% of patients had a response duration of
24 months (Figure 2D). 7% and 3% of patients in the afatinib
and methotrexate groups, respectively, continued treatment be-
yond progression.
Most patients in the afatinib and methotrexate arms filled out
both QLQ-C30 and QLQ-HN35 questionnaires at each visit
(95.2% versus 93.8% at randomisation; 69.1% versus 63.3% at
end of treatment). More afatinib-treated patients than
methotrexate-treated patients reported improvements in QLQ-
C30 global health status/quality of life (40% versus 23%) and
Table 1. Patient demographics and baseline disease characteristics
Characteristic Afatinib
(n5228)
Methotrexate
(n5 112)
Sex, n (%)
Male 193 (85) 99 (88)
Female 35 (15) 13 (12)
Age, years
Median (range) 55.5 (28–83) 58.0 (27–76)
<65, n (%) 197 (86) 96 (86)
65, n (%) 31 (14) 16 (14)
Race, n (%)
Asian 215 (94) 107 (96)
White 13 (6) 5 (4)
Region, n (%)
East Asia 131 (58) 78 (70)
Other 97 (42) 34 (30)
ECOG performance status, n (%)
0 47 (21) 24 (21)
1 181 (79) 88 (79)
Smoking pack-years, n (%)
<10 107 (47) 46 (41)
10 120 (53) 66 (59)
Unknown 1 (<1) 0 (0)
Alcohol consumption, n (%)
7 units/week 179 (79) 84 (75)
>7 units/week 49 (21) 27 (24)
Unknown 0 (0) 1 (<1)
Primary tumour site, n (%)
Oral cavity 115 (50) 50 (45)
Oropharynx 29 (13) 18 (16)
Hypopharynx 26 (11) 17 (15)
Larynx 57 (25) 27 (24)
Other 1 (<1) 0 (0)
Time since first diagnosis, years
Median (range) 1.6 (0.2–21.3) 1.7 (0.2–12.9)
<2, n (%) 149 (65) 72 (64)
2, n (%) 79 (35) 40 (36)
Localisation of recurrence, n (%)
Locoregional disease only 114 (50) 59 (53)
Distant metastases only 17 (8) 7 (6)
Both 96 (42) 46 (41)
Unknown 1 (<1) 0 (0)
Metastatic sites, n (%)
Any 112 (49) 51 (46)
Non-regional lymph nodes 50 (22) 20 (18)
Lung 76 (33) 39 (35)
Liver 11 (5) 4 (4)
Bone 8 (4) 6 (5)
Skin 1 (<1) 1 (<1)
Other 10 (4) 4 (4)
p16 status,a n (%)
Positive 9 (4) 1 (<1)
Negative 79 (35) 30 (27)
No result available 140 (61) 81 (72)
Differentiation grade, n (%)
Well differentiated 66 (29) 28 (25)
Moderately differentiated 90 (40) 41 (37)
Poorly differentiated 32 (14) 16 (14)
Continued
Table 1. Continued
Characteristic Afatinib
(n5 228)
Methotrexate
(n5112)
Undifferentiated 2 (<1) 0 (0)
Not specified/unknown 38 (17) 27 (24)
Prior platinum-based therapy for R/M disease, n (%)
Cisplatin 171 (75) 79 (71)
Carboplatin 42 (18) 23 (21)
Cisplatin and carboplatin 7 (3) 3 (3)
Other 5 (2) 7 (6)
Prior use of anti-EGFR mAb for
R/M disease, n (%)b
30 (13) 13 (12)
Duration of anti-EGFR mAb for R/M disease, n (%)
12 weeks 13 (6) 4 (4)
>12–24 weeks 9 (4) 6 (5)
>24 weeks 8 (4) 3 (3)
Prior surgery, n (%) 176 (77) 88 (79)
Prior anticancer therapy for early-stage or LA disease, n (%)
RT only 66 (29) 43 (38)
CRT 86 (38) 34 (30)
CT alone 7 (3) 1 (<1)
CTþRTþEGFR-targeted mAb 7 (3) 1 (<1)
Other 3 (1) 1 (<1)
aBased on central test results.
bNine patients received prior nimotuzumab and the remaining patients
received cetuximab.
CRT, chemoradiation therapy; CT, chemotherapy; ECOG, Eastern
Cooperative Oncology Group; EGFR, epidermal growth factor receptor;
LA, locally advanced; mAb, monoclonal antibody; R/M, recurrent or meta-
static; RT, radiation therapy.
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Figure 1. Survival outcomes. (A) Kaplan–Meier estimates of progression-free survival assessed by independent review. (B) Pre-specified sub-
group analysis of progression-free survival (independent review). CI, confidence interval; CR, complete response; ECOG PS, Eastern
Cooperative Group Performance Status; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; HR, hazard
ratio; PD, progressive disease; PFS, progression-free survival; PR, partial response; R/M, recurrent or metastatic; SD, stable disease. *Cisplatin
alone, cisplatinþcarboplatin, nedaplatin alone and other.
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swallowing symptoms (34% versus 18%; supplementary Figure
S4, available at Annals of Oncology online). Rates of analgesic use
were 59% for afatinib-treated patients and 63% for
methotrexate-treated patients (OR 0.65; 95% CI 0.38–1.10;
P¼ 0.11). Patients receiving afatinib had a greater mean change
in global health status than patients receiving methotrexate (22.9
versus 15.0; difference 7.9, 95% CI 3.5–12.4; P¼ 0.0005; supple-
mentary Figure S4, available at Annals of Oncology online).
Median time to deterioration in global health status, pain and
swallowing scores are shown in supplementary Table S1, available
at Annals of Oncology online.
Median duration of treatment was 91.5 days [interquartile
range (IQR) 49.0–170.5] in the afatinib group, and 42.5 days
(IQR 24.5–79.5) in the methotrexate group. Grade 3 AEs
occurred in 50% of afatinib-treated patients and 45% of
methotrexate-treated patients (supplementary Table S2, available
at Annals of Oncology online); 16% and 23%, respectively, were
drug-related (Table 2). The most frequent grade3 drug-related
Figure 2. Disease control and tumour shrinkage. (A) Objective response rate and disease control rate with afatinib and methotrexate,
assessed by independent review. (B) Prespecified subgroup analyses of objective response rate (independent review). (C) Maximum percent-
age tumour shrinkage in individual patients. (D) Duration of response for individual patients. CI, confidence interval; CR, complete response;
ECOG PS, Eastern Cooperative Group Performance Status; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell car-
cinoma; PD, progressive disease; PR, partial response; R/M, recurrent or metastatic; SD, stable disease. *Cisplatin alone, cisplatinþcarboplatin,
nedaplatin alone and other.
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AEs were rash/acne (4%), diarrhoea (4%), and stomatitis (3%)
with afatinib, and anaemia, fatigue and leukopenia (all 5%) with
methotrexate (Table 2). Drug-related AEs led to dose reductions
in 22% and 29% of patients in the afatinib and methotrexate
groups, respectively (supplementary Table S3, available at Annals
of Oncology online), and to discontinuation in 11% and 17% of
patients.
Serious AEs occurred in 40% and 35% of patients treated with
afatinib and methotrexate; these were considered drug-related in
8% and 15% of patients, respectively. Fatal AEs occurred in 23%
and 11% of patients; of these, two deaths (<1%) in the afatinib
group (hypoglycaemia and lung infiltration/pneumonitis) and
four (4%) in the methotrexate group (lung infection, pneumo-
nia, respiratory failure, and tumour haemorrhage) were consid-
ered drug-related. In the afatinib group, most fatal AEs were
considered related to disease progression (n¼ 28). Most fatal AEs
(77% and 82% in the afatinib and methotrexate groups,
respectively) occurred after termination of treatment. The rate of
fatal AEs adjusted by time at risk was 0.51 event/patient year for
afatinib and 0.43 event/patient year for methotrexate.
Among the patients who discontinued study treatment, 32% of
the afatinib-treated patients and 38% of the methotrexate-treated
patients received subsequent anticancer therapy (supplementary
Table S4, available at Annals of Oncology online).
Discussion
This study demonstrated a significant, clinically meaningful, im-
provement in PFS with afatinib versus methotrexate in Asian
patients with recurrent/metastatic HNSCC. Importantly, PFS
benefit was generally consistent across prespecified patient sub-
groups and over time. While the difference in median PFS be-
tween the two treatment groups was numerically small (2.9
Figure 2. Continued.
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versus 2.6 months, respectively), the HR, which summarises the
treatment difference over the entire duration of the trial, fav-
oured afatinib [12]. Furthermore, the PFS benefit with afatinib
was substantiated by the high response rates and patient-reported
HRQoL benefits versus methotrexate. The reduction in risk of
progression/death was greater in LUX-Head & Neck 3 than LUX-
Head & Neck 1. While there was no significant difference in OS
with afatinib versus methotrexate, the study was not powered to
detect an OS benefit.
In this study, the p16 status of tumours was not available for
over 60% of patients. Nevertheless, based on available data, a
high proportion of patients had p16-negative tumours, as
expected for an Asian population, indicating low rates of HPV-
related HNSCC [1315]. Interestingly, HPV-negative disease
has been associated with EGFR amplifications [16], suggesting
HPV-negative patients may derive particular benefit from EGFR-
targeted therapy. The PFS benefit in p16-negative patients seen
here is in line with that observed in LUX-Head & Neck 1, albeit
based on fewer patients with available p16 status, and is consist-
ent with this hypothesis. In both studies, particular PFS benefit
was also seen in EGFR pre-treatment-naı¨ve patients and those
who had not responded to prior platinum therapy. Future ap-
proval of immunotherapeutic drugs in a first-line setting will
likely increase the proportion of patients who are EGFR pre-
treatment-naı¨ve at the onset of second-line treatment.
Owing to the potential impact of HNSCC on basic activities
such as breathing, swallowing and speaking, effective, and pro-
longed tumour reduction is particularly important [17, 18].
Although direct cross-trial comparisons are not possible, given
differences in study populations and design, the ORR with afati-
nib (28%) was of interest in the context of other monotherapy
studies in the second-line setting, where rates of 4%–14% are
common with single-agent methotrexate, paclitaxel, and
cetuximab [19, 20]. Furthermore, while both pembrolizumab
and nivolumab have demonstrated significant OS benefit versus
standard care in this setting, the ORR was only 15% and 13%, re-
spectively, although median duration of response was consider-
ably higher than observed with afatinib in the current study [4,
5]. Of note, the ORR with afatinib was higher than seen in LUX-
Head & Neck 1 (10%), possibly reflecting differences in the pro-
portions of p16-negativity and EGFR pre-treatment [6]. Indeed,
in LUX-Head & Neck 1, higher ORRs were seen in patients with
p16-negative disease (14%) and EGFR pre-treatment-naı¨ve
patients (20%) than in the overall population [6], with an ORR
of 28% reported for EGFR pre-treatment naı¨ve patients who also
had p16-negative disease [21].
The improvements in swallowing symptoms and global health
status with afatinib further demonstrate the clinical relevance of
our findings. While there was no significant reduction in pain
symptoms, the reduced use of analgesics with afatinib versus
methotrexate is encouraging. While stable scores across the
European Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 functional and symptom domains were
reported with nivolumab in the CheckMate 141 study [22], as
yet, there are limited data on the effects of other targeted thera-
pies on patient-reported outcomes in recurrent/metastatic
HNSCC, limiting comparisons of different treatment options.
The safety profile of afatinib was in line with previous clinical
experience with afatinib, including LUX-Head & Neck 1 [6], with
the most common AEs (diarrhoea, rash and stomatitis) being
EGFR-mediated events. However, few AEs were grade 3, and
discontinuations due to AEs were uncommon, suggesting that,
per previous clinical experience, they can be readily managed
with appropriate treatment and tolerability-guided dose
Table 2. Most common drug-related adverse events (10% of patients in either treatment group)
Afatinib (n5228) Methotrexate (n5 104)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Any drug-related adverse event 165 (72) 32 (14) 3 (1) 2 (<1) 46 (44) 16 (15) 4 (4) 4 (4)
Diarrhoea 145 (64) 8 (4) 0 0 6 (6) 0 0 0
Rash/acnea 116 (51) 10 (4) 0 0 4 (4) 0 0 0
Stomatitisb 79 (35) 7 (3) 0 0 24 (23) 1 (1) 1 (1) 0
Paronychiac 40 (18) 2 (<1) 0 0 0 0 0 0
Dermatitis acneiform 27 (12) 1 (<1) 0 0 0 0 0 0
Mouth ulceration 23 (10) 1 (<1) 0 0 6 (6) 0 0 0
Fatigued 11 (5) 3 (1) 0 0 12 (12) 5 (5) 0 0
Anaemia 6 (3) 1 (<1) 0 0 6 (6) 5 (5) 0 0
Leukopeniae 3 (1) 0 0 0 17 (16) 2 (2) 3 (3) 0
Increased alanine aminotransferase 3 (1) 0 0 0 12 (12) 1 (1) 0 0
Neutropenia 0 0 0 0 8 (8) 1 (1) 2 (2) 0
aGrouped term including acne, blister, dermatitis, dermatitis acneiform, eczema, erythema, folliculitis, rash, rash maculo-papular, rash pustular, skin exfoli-
ation, skin fissures, skin lesion, skin reaction, and skin ulcer.
bGrouped term including aphthous ulcer, mouth ulceration, mucosal erosion, mucosal inflammation, and stomatitis.
cGrouped term including nail bed infection and paronychia.
dGrouped term including asthenia, fatigue, lethargy, malaise.
eGrouped term including leukopenia and decreased white blood cell count.
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modification. The results demonstrated the feasibility of pro-
longed afatinib treatment, with a median treatment duration
more than double that of methotrexate. While the incidence of
fatal AEs was higher in the afatinib group versus the methotrexate
group, few of these deaths were considered treatment related. The
incidence of fatal AEs considered drug-related was similar to that
seen in LUX-Head & Neck 1 (<1% in the afatinib group and 3%
in the methotrexate group). The difference in the total incidence
of fatal AEs between the afatinib and methotrexate groups in
LUX-Head & Neck 3 could reflect the longer duration of expos-
ure with afatinib versus methotrexate.
One potential limitation of our study is the choice of metho-
trexate as a comparator. However, methotrexate is a globally
accepted second-line treatment and is widely used in Asian coun-
tries, where the newer anti-PD1 immunotherapies are often un-
available. Furthermore, LUX-Head & Neck 3 was not designed or
powered to detect an OS benefit, and many patients will likely
have received subsequent therapies beyond second-line treat-
ment, limiting interpretation of the OS results. Finally, owing to
the different administration routes, patients and clinicians were
not blinded to study group, possibly confounding reporting of
AEs.
In summary, LUX-Head & Neck 3 substantiates the previous
LUX-Head & Neck 1 study, further demonstrating the feasibility
of oral afatinib as a second-line treatment option for patients
with recurrent/metastatic HNSCC. These results are of particular
relevance for patients in Asian countries, where there are high
rates of HPV-negative disease and low rates of EGFR pre-
treatment. They could also have wider global relevance if im-
munotherapy agents are approved in the first-line setting [2], a
change that is likely to increase the proportion of second-line
patients who are EGFR treatment-naı¨ve. In this regard, further
research is needed to evaluate the efficacy of afatinib in the post-
immunotherapy setting.
Data sharing
The clinical study report (including appendices, but without line
listings) and other clinical documents related to this study may
be accessed on request. Before providing access, the documents
and data will be examined, and, if necessary, redacted and de-
identified to protect the personal data of study participants and
personnel, and to respect the boundaries of the informed consent
of the study participants. See https://trials.boehringer-ingelheim.
com/data_sharing/sharing.html#accordion-1-2 for further
details. Bona fide, qualified scientific and medical researchers
may request access de-identified, analysable patient-level study
data, together with documentation describing the structure
and content of the datasets. Researchers should use https://clini
calstudydatarequest.com/ to request access to raw data from this
study.
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